PharmStockPharmacy Stock

Gleevec
Gleevec

10.63
A generic medicine indicated for oncology care. Addresses specific cell signaling pathways to inhibit the progression of oncological conditions.
Ingredient
Imatinib
Category
Oncology Support
Availability
In Stock
Delivery Time
Airmail (14-21 days) | Trackable (5-9 days)
Shipped in a discreet, unmarked envelope with all required documents enclosed.

Product Sheet

Active Ingredient(s)
Imatinib mesylate
Reference Brand
Imatinib
Product Origin
Generic Alternative
Reference Manufacturer
Novartis
Product Form
Tablet
Regulatory Classification
Prescription Only Medicine
Primary Category
Pain Relief
Product Category
Tyrosine Kinase Inhibitor
Pharmacological Class
Antineoplastic
Manufacturer Description
Designed to support neoplastic cellular control to manage myeloid leukemia and alleviate tumor tissue progression.
Mechanism of Action
Inhibits the Bcr-Abl tyrosine kinase enzyme, halting signaling pathways that trigger neoplastic cellular proliferation.
Route of Administration
Oral
Onset Time
1–2 weeks
Duration
24 hours
Contraindications
Severe hypersensitivity to imatinib
Severe Adverse Events
Severe hepatotoxicity — requires immediate medical attention, Severe bone marrow suppression — requires immediate medical attention
Common Side Effects
Nausea, Vomiting, Diarrhea
Uncommon Side Effects
Fluid retention, Muscle cramps, Fatigue
Drug Interactions
Ketoconazole, Rifampin, Warfarin
Pregnancy Safety Warnings
TGA Category D: High risk of fetal toxicity. Do not use during pregnancy. Breastfeeding: Avoid.
Age Restrictions
Approved for pediatric and adult populations.
Storage Guidelines
Store below 25°C.
Related Products
Sprycel
Information related to Gleevec is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
Categories
how to buy Hormonal Health Tablets - Medroxyprogesterone Progesterone Women's Tablet